Clinical trials: Donor Lymphocyte Infusion
Myelodysplastic Syndrome
Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation
The purpose of this study is to evaluate the feasibility and efficacy of reduced-intensity conditioning allogeneic HCT followed by prophylactic dose-escalating DLIs in patients with higher risk MDS.
- Trial name
- RICandDLI (NCT01252784)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Cooperative Study Group A for Hematology
Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL)
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Background: Most patients with acute lymphoblastic leukemia (ALL) and many patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and non-Hodgkin's lymphoma (NHL) have a protein called Wilm's Tumor 1…
- Conditions
- Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL), Leukemia, Chronic Myelogenous (CML), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT00923910
- Testing
- WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic Organs; Disorder
CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation
In this clinical trial, the investigators aim to apply CD62L depleted donor lymphocyte infusion (DLI) together with in vitro T cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) to treat patients with…
- Trial name
- NCT06034535
- Testing
- CD62L depleted donor lymphocyte infusion
- Where
- Hong Kong
- Volunteers
- 23 people
- Sponsor
- Hong Kong Children's Hospital
Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
This is a phase I/II study of highly selected donor lymphocyte infusions in patients undergoing HLA-haploidentical hemopoietic stem cell transplantation. Patients will be offered "pre-emptive" NK-DLI early after HSCT.
- Conditions
- Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic Syndromes, Lymphoma
- Trial name
- NCT01386619
- Testing
- CD3-depleted/CD56+ selected natural killer cells collected from apheresis products
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 15 people
- Sponsor
- University Hospital, Basel, Switzerland
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
This phase I/II trial studies the side effects and best dose of donor natural killer (NK) cell therapy and to see how well it works when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, donor…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT00789776
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Fred Hutchinson Cancer Center
Immunodeficiency
Donor Lymphocyte Infusion After Alternative Donor Transplantation
The purpose of this study is to determine the ability of a donor lymphocyte infusion (DLI) given with methotrexate to hasten immune recovery without causing severe graft-versus-host disease (GVHD) in recipients who have had a…
- Trial name
- NCT01027702
- Testing
- Infusion of donor lymphocytes
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Wake Forest University Health Sciences
CMV Infection, EBV
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
To assess the safety and biological efficacy of therapeutically administered most closely HLA-matched third party donor-derived specific cytotoxic T lymphocytes (CTLs) targeting cytomegalovirus (CMV) or Adenovirus (Adv) or…
- Conditions
- CMV Infection, EBV, Adenovirus
- Trial name
- R3ACT (NCT02779439)
- Testing
- Virus specific CTLs
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Sydney
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00096161
- Testing
- Cyclosporine, Mycophenolate Mofetil, Pentostatin
- Where
- 5 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders
Stem Cell Transplant for Immunologic or Histiocytic Disorders
This study tests the clinical outcomes of a preparative regimen of fludarabine (FLU), anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell transplant, and a post transplant regimen of…
- Conditions
- Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome
- Trial name
- NCT00176865
- Testing
- Stem Cell Transplant, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse.
- Conditions
- Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation, Acute Leukemia, Minimal Residual Disease
- Trial name
- NCT03297528
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Relapsed Adult ALL, Relapsed Adult AML
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
Acute leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), is the subtype of leukemia with the highest mortality, and leukemia relapse caused by the protective bone marrow microenvironment is…
- Trial name
- NCT06141304
- Testing
- Plerixafor
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The First Hospital of Jilin University
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Leukemia
Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation
Pilot, multicentric, open-label, single-arm, phase I-II clinical trial to evaluate the safety and efficacy of a novel Umbilical Cord Blood Transplantation (UCBT) platform, that consists of a UCBT of the 80 fraction, followed by a…
- Trial name
- NCT02328885
- Testing
- DLI of the 20 fraction of the UCBT
- Where
- 5 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Banc de Sang i Teixits
Donor Lymphocyte Infusion, Peripheral Blood Stem Cell Transplantation
Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies
Unmanipulated allogenic peripheral blood stem cell transplantation (allo-PBSCT) has been an established treatment to cure high-risk leukemia/lymphoma.
- Conditions
- Donor Lymphocyte Infusion, Peripheral Blood Stem Cell Transplantation, Relapse, Graft-versus-host Disease
- Trial name
- NCT03771222
- Testing
- Prophylactic DLI
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese PLA General Hospital
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00823524
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Leukemia, Relapse
Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia
A single-arm trial to evaluate the effectiveness and safety of Blinatumomab and Donor Lymphocyte Infusion in maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk Ph negative B cell acute…
- Trial name
- NCT07105579
- Testing
- BITE and DLI
- Where
- China
- Volunteers
- 31 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Leukemia, Myelodysplastic Syndromes
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
RATIONALE: Giving total-body irradiation and chemotherapy, such as thiotepa and fludarabine, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Trial name
- NCT00376480
- Testing
- anti-thymocyte globulin, peripheral blood lymphocyte therapy, fludarabine phosphate
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Lymphoma
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00534118
- Testing
- donor lymphocytes
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor peripheral blood stem cell transplant helps stop both the growth of cancer cells and the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00301860
- Testing
- anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Two key methods of GVHD prevention in allogeneic HSCT have a number of limitations: ex vivo T depletion is associated with an excess of infectious complications, and pharmacological immunosuppression with insufficient efficacy of…
- Conditions
- Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk, Acute Lymphoblastic Leukemia, Relapse
- Trial name
- NCT07366801
- Testing
- Cyclosporine A (CsA), Sirolimus, Ruxolitinib (JAKAVI®)
- Where
- Russia
- Volunteers
- 64 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology